BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 04/01/24
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific ConferencePRNewsWire • 02/27/24
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSPRNewsWire • 02/23/24
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 01/02/24
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the FirmBusiness Wire • 12/31/23
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLIPRNewsWire • 12/30/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLIPRNewsWire • 12/29/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)Business Wire • 12/28/23
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their OptionsPRNewsWire • 12/28/23
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud LawsuitPRNewsWire • 12/27/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the FirmAccesswire • 12/27/23
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder TreatmentsPRNewsWire • 12/26/23
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 12/23/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the FirmAccesswire • 12/22/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)PRNewsWire • 12/18/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 12/14/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $500,000 to Contact the FirmAccesswire • 12/11/23
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 12/08/23
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their OptionsPRNewsWire • 12/05/23
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the FirmAccesswire • 12/04/23
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their OptionsPRNewsWire • 11/30/23
